Search results for "Prostatic Hyperplasia"

showing 10 items of 30 documents

Relationship between PTH and PSA Values in Patients with Pathological Finding of Benign Prostatic Hyperplasia

2012

The functional relationship between parathyroid glands and prostatic gland is commonly very well known. The aim of our study was to investigate the relationship between serum levels of PTH and serum levels of PSA in patients with pathological finding of BPH. According to 261 transrectal ultrasound-guided prostatic biopsies performed from March 2009 to March 2010, 75 patients, responding to our inclusion criteria, were selected. 26 patients (34.6%) ended the study. All patients with high serum levels of PSA (>4 ng/mL), with histological diagnosis of benign prostatic hyperplasia, underwent the assay of serum levels of PTH. We observed high levels of PTH (> 66 pg/mL) in 9 patients (35.2…

MaleProstatic GlandAgingmedicine.medical_specialtyBiopsyProstatic HyperplasiaUrologyProstatic biopsyHistological diagnosisBiopsymedicineHumansIn patientPathologicalAgedCalcifediolAged 80 and overmedicine.diagnostic_testbusiness.industryHigh serumProstateGeneral MedicineMiddle AgedProstate-Specific AntigenHyperplasiamedicine.diseaseParathyroid HormonebusinessUrologia Journal
researchProduct

Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis

2003

Background: The study of the expression of different biological markers in non-neoplastic, pre-neoplastic and neoplastic lesions of prostate could help to better understand their role in carcinogenesis and to find new diagnostic and prognostic tools. Materials and Methods: In the present work we evaluated, by immunohistochemistry, the presence and the expression of PCNA, p53, HSP60, HSP10 and MUC-2 in a series of nodular hyperplasia, low- and high-grade prostatic intraepithelial lesions and adenocarcinomas. Results: Our data confirmed that: 1) PCNA expression could be related to the grade of progression of cancer; and that 2) p53 mutation could be a late event in prostate carcinogenesis. Mo…

MaleProstatic Intraepithelial NeoplasiaMucin-2Cancer ResearchGene Expression ProfilingMucinsProstatic HyperplasiaProstateProstatic NeoplasmsCarcinogenesis; Heat-shock proteins; Prostate; Cancer Research; OncologyCell DifferentiationChaperonin 60AdenocarcinomaGenes p53ImmunohistochemistryNeoplasm ProteinsHeat-shock proteinCell Transformation NeoplasticOncologyProliferating Cell Nuclear AntigenChaperonin 10Disease ProgressionHumansTumor Suppressor Protein p53Carcinogenesi
researchProduct

Sexual dysfunctions after transurethral resection of the prostate (TURP): evidence from a retrospective study on 264 patients

2015

Objectives: Benign prostatic hyperplasia (BPH) and sexual dysfunctions are diseases with a high prevalence in aged men. Several studies have found a link between BPH and LUTS resulting from deterioration in sexual function in men aged 50 years and older for whom TURP is considered the gold standard. The impact of TURP on sexual functions still remain uncertain, nor is it clear what pathophysiological mechanism underlying the emergence of new episodes of Erectile Dysfunction (ED) following TURP in patients with normal sexual function before surgery, while retrograde ejaculation and ejaculate volume reduction represent a clear side effect; derived from BPH treatment. The aim of this study was…

MaleRetrograde ejaculationmedicine.medical_specialtyLongitudinal studyUrologymedicine.medical_treatmentProstatic Hyperplasialcsh:RC870-923urologic and male genital diseasesPreoperative careSettore MED/24 - UrologiaErectile DysfunctionErectile Dysfunction (ED)Surveys and QuestionnairesInternal medicinePreoperative CaremedicineHumansInternational index of erectile function (IIEF)Longitudinal StudiesSicilyTransurethral resection of the prostate (TURP)AgedRetrospective StudiesTransurethral resection of the prostateAged 80 and overPostoperative CareLibidoBenign prostatic hyperplasiabusiness.industryBenign prostatic hyperplasia (BPH)Low urinary tract symptoms (LUTS).Transurethral Resection of ProstateTransurethral resection of the prostateRetrospective cohort studyMiddle Agedlcsh:Diseases of the genitourinary system. Urologymedicine.diseaseInternational index of erectile functionLow urinary tract symptomsSurgeryErectile dysfunctionSexual functionbusinessArchivio Italiano di Urologia e Andrologia
researchProduct

Re: Tamsulosin and the Risk of Dementia in Older Men with Benign Prostatic Hyperplasia.

2018

MaleRiskTamsulosinmedicine.medical_specialtybusiness.industryUrology030232 urology & nephrologyMEDLINEUrologyProstatic HyperplasiaHyperplasiamedicine.disease03 medical and health sciences0302 clinical medicineTamsulosin030220 oncology & carcinogenesisAdrenergic alpha-1 Receptor AntagonistsMedicineDementiaHumansDementiabusinessmedicine.drugEuropean urology
researchProduct

Cognitive and mood side effects of lower urinary tract medication

2019

Introduction: Muscarinic receptor antagonists, 5α-reductase inhibitors and α1-adrenoceptor antagonists are frequently used drug classes for the treatment of lower urinary tract symptoms including those of overactive bladder syndrome and benign prostatic enlargement/benign prostatic obstruction. Areas covered: The authors review the evidence for adverse effects of these drug classes on cognitive function, mood and other functions of the central nervous system and discuss such effects against the evidence for mechanistic plausibility. Expert opinion: Muscarinic antagonists carry a risk for impaired cognition and other brain functions that differs quantitatively between compounds, being highes…

MaleTamsulosinmedicine.medical_specialtyUrinary systemProstatic HyperplasiaMuscarinic Antagonists030204 cardiovascular system & hematology03 medical and health sciences5-alpha Reductase InhibitorsCognition0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsTamsulosinInternal medicinemedicineAnimalsHumansDementiaPharmacology (medical)OxybutyninAdverse effectDose-Response Relationship DrugUrinary Bladder Overactivebusiness.industryGeneral Medicinemedicine.diseaseDiscontinuationAffectMood030220 oncology & carcinogenesisAdrenergic alpha-1 Receptor Antagonistsbusinessmedicine.drugExpert Opinion on Drug Safety
researchProduct

Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate

2021

Background: Although an increasing number of prostate cancer (PCa) patients received holmium laser enucleation of the prostate (HoLEP) previously for benign prostatic obstruction (BPO), there is still no evidence regarding the outcomes of radical prostatectomy (RP) in this setting. Objective: To assess functional and oncological results of RP in PCa patients who received HoLEP for BPO previously in a contemporary multi-institutional cohort. Design, setting, and participants: A total of 95 patients who underwent RP between 2011 and 2019 and had a history of HoLEP were identified in two institutions. Functional as well as oncological follow-up was prospectively assessed and retrospectively an…

Malemedicine.medical_specialtyHolmium laser enucleation of the prostate; Localized prostate cancer; Patient-reported outcomes; Radical prostatectomy; Urinary continenceUrologymedicine.medical_treatmentEnucleation030232 urology & nephrologyUrologyProstatic HyperplasiaUrinary incontinenceLasers Solid-State03 medical and health sciencesBladder outlet obstructionProstate cancerHolmium0302 clinical medicineErectile DysfunctionmedicineHumansRetrospective StudiesProstatectomyLocalized prostate cancerPatient-reported outcomesProstatectomybusiness.industryHazard ratioProstateUrinary continenceOdds ratiomedicine.diseaseRadical prostatectomyHolmium laser enucleation of the prostate030220 oncology & carcinogenesisPropensity score matchingmedicine.symptombusiness
researchProduct

Predictive variables of spontaneous micturition recovery after acute urinary retention in men with benign prostatic enlargement: An observational pro…

2017

Objective: Acute urinary retention (AUR) is the sudden and painful inability to urinate spontaneously. AUR is one of the most significant complications of benign prostatic enlargement. The management of AUR is based on transurethral catheterization. Subsequent therapy is uncertain, but AUR seems to benefit from the use of alpha-blockers. The aim of this study was to evaluate the variables that could predict which patients would recover spontaneous micturition after trial without catheter. Methods: The present prospective observational study included men with AUR in an Italian tertiary care institute in 2016. Patients were catheterized and treated orally with fluoroquinolones, alpha-blockers…

Malemedicine.medical_specialtyNeurologymedia_common.quotation_subjectUrology030232 urology & nephrologyUrologyProstatic HyperplasiaUrinationUrinationSeverity of Illness IndexC-reactive protein03 medical and health sciences0302 clinical medicineProstatemedicineHumansProspective Studiesacute urinary retentionProspective cohort studymedia_commonAgedspontaneous micturition recoveryInternational Prostate Symptom ScorebiologyUrinary retentionbusiness.industryC-reactive proteinArea under the curveProstateOrgan SizeRecovery of FunctionMiddle AgedUrinary Retentionmedicine.anatomical_structureROC CurveNeurology030220 oncology & carcinogenesisArea Under CurveAcute Diseasebiology.proteinInternational Prostate Symptom Scoremedicine.symptombusinessUrinary Catheterization
researchProduct

Symptomatology and Diagnosis of Benign Prostatic Hyperplasia

1991

The symptoms of benign prostatic hyperplasia are well known. Diagnosis rests on digital palpation of the enlarged prostate. Objective parameters are laboratory tests, imaging techniques, endoscopy, and urodynamic investigations. Laboratory tests include urinalysis and serum creatinine measurement. Markers are not reliable and the determination of acid phosphatase and prostate-specific antigen is not recommended routinely for patients with prostatism. Imaging techniques are usually restricted to a complete echographic investigation of the entire urinary tract. Endoscopic manipulations are seldom necessary. Uroflow measurements are customarily performed, but the need for a complete urodynamic…

Malemedicine.medical_specialtyPathologymedicine.diagnostic_testUrinalysisbusiness.industryUrologyDigital palpationUrinary bladder neck obstructionProstatic HyperplasiaUrination disorderSerum Creatinine MeasurementHyperplasiaUrination Disordersmedicine.diseaseEndoscopyUrinary Bladder Neck ObstructionUrodynamicsHumansMedicineProstatismRadiologybusinessEuropean Urology
researchProduct

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

2013

To present a summary of the 2013 version of the European Association of Urology guidelines on the treatment and follow-up of male lower urinary tract symptoms (LUTS). We conducted a literature search in computer databases for relevant articles published between 1966 and 31 October 2012. The Oxford classification system (2001) was used to determine the level of evidence for each article and to assign the grade of recommendation for each treatment modality. Men with mild symptoms are suitable for watchful waiting. All men with bothersome LUTS should be offered lifestyle advice prior to or concurrent with any treatment. Men with bothersome moderate-to-severe LUTS quickly benefit from α1-blocke…

Malemedicine.medical_specialtyPhosphodiesterase Inhibitorsmedicine.medical_treatmentUrologyUrologyProstatic HyperplasiaMuscarinic AntagonistsSeverity of Illness Indexchemistry.chemical_compound5-alpha Reductase InhibitorsLower Urinary Tract SymptomsLower urinary tract symptomsmedicineNocturiaHumansWatchful WaitingTransurethral resection of the prostateUrinary retentionProstatectomybusiness.industryTransurethral Resection of Prostatemedicine.diseaseDutasterideTreatment OutcomechemistryAdrenergic alpha-1 Receptor AntagonistsUrological AgentsProstate surgeryStentsmedicine.symptombusinessUrinary CatheterizationRisk Reduction BehaviorWatchful waitingEuropean urology
researchProduct

Outcome of radical prostatectomy for incidental carcinoma of the prostate

2009

OBJECTIVE To evaluate a contemporary series of patients with incidental prostate cancer detected by transurethral resection of the prostate (TURP) and undergoing radical prostatectomy (RP). PATIENTS AND METHODS Between 1998 and 2004, 1931 patients had TURP for obstructive voiding symptoms and suspected BPH. Incidental prostate cancer was found in 104 (5.4%); 26 of these patients had a RP. The pathological staging and treatment of these patients were reviewed retrospectively and the follow-up results obtained. RESULTS Of the 26 patients who had RP, 17 had T1a and nine had T1b carcinoma of the prostate. After RP, six (35%) in the T1a group had no residual tumour (pT0) and 11 (65%) had pT2 can…

Malemedicine.medical_specialtyProstate biopsyUrologymedicine.medical_treatmentPathological stagingProstatic HyperplasiaUrologyurologic and male genital diseasesProstate cancerProstatemedicineHumansAgedTransurethral resection of the prostateProstatectomyIncidental Findingsmedicine.diagnostic_testbusiness.industryProstatectomyProstatic NeoplasmsCancerMiddle AgedProstate-Specific Antigenmedicine.diseaseTreatment Outcomemedicine.anatomical_structureHormonal therapyEpidemiologic MethodsbusinessProstatismBJU International
researchProduct